Dr Zev Wainberg speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.

He outlines the background, and study design for this phase I/II trial, which investigated first-line liposomal irinotecan irinotecan plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in patients with pancreatic ductal adenocarcinoma.

Dr Wainberg states that a safe and tolerable dose for this regimen was established, with compelling efficacy. For this regimen, progression-free survival of 9.5 months, and a median overall survival of 12.5 months was achieved in this patient population.

He also explains the toxicity profile and the next steps for this study - which includes the launch of a the phase III NAPOLI-3 trial.